Viewing data from:

VINORELBINE TARTRATE

ANDA

VINORELBINE TARTRATE | A075992 | HIKMA PHARMACEUTICALS USA INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Vinorelbine Tartrate (2023)

Total Spending

$13K

Total Claims

Beneficiaries

Avg Cost/Unit

$16.01

Spending Trend

$24K(2019)→$28K(2020)→$27K(2021)→$23K(2022)→$13K(2023)

YoY Change:-12.6%

5yr CAGR:-1.5%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain3 active DMFs8 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

PIERRE FABRE MEDICAMENTVINORELBINE TARTRATE

DMF 94771991

MINAKEM HIGH POTENTVINORELBINE TARTRATE

DMF 146191999

HUBEI HONCH PHARMACEUTICAL CO LTDVINORELBINE TARTRATE

DMF 260912013

ZHEJIANG HISUN PHARMACEUTICAL CO LTDInactiveVINORELBINE TARTRATE USP

DMF 159562002

JIANGSU HANSOH PHARMACEUTICAL GROUP CO LTDInactiveVINORELBINE TARTRATE USP

DMF 160112002

EXOPHARM CO LTDInactiveVINORELBINE TARTRATE (NON-STERILE BULK DRUG SUBSTANCE)

DMF 190942006

CIPLA LTDInactiveVINORELBINE TARTRATE USP

DMF 201582009

SYNBIAS PHARMA LTDInactiveVINORELBINE TARTRATE

DMF 219292008

ALP PHARM BEIJING CO LTDInactiveVINORELBINE TARTRATE

DMF 239512010

QILU PHARMACEUTICAL CO LTDInactiveVINORELBINE TARTRATE (PROCESS I) (NON STERILE, API)

DMF 252032011

SYNBIAS PHARMA AGInactiveVINORELBINE TARTRATE

DMF 282212014

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (1)

#001 — EQ 10MG BASE/ML

0 patents0 exclusivities▴

INJECTABLE;INJECTION | Approved: Jun 10, 2003

No patent or exclusivity listings for this strength.